Navigation Links
Millennium HealthCare Signs Distribution Agreement with Atossa Genetics
Date:5/2/2013

GARDEN CITY, N.Y., May 2, 2013 /PRNewswire/ -- Millennium HealthCare Inc. (OTC Pink: MHCC) today announced that its Medical Device subsidiary signed an agreement with Atossa Genetics Inc. (NASDAQ: ATOS) for the distribution of Atossa's ForeCYTE Breast Health devices, which consist of the patented MASCT pump and ForeCYTE patient collection kits. Millennium has submitted an initial order for 10,000 ForeCYTE collection kits, which it intends to market to managed-care networks, healthcare clinics and physician practices in the New York Metro Area and Northern New Jersey.

Atossa's MASCT system is used by physicians and nurses to collect a small amount of nipple aspirate fluid for analysis by the National Reference Laboratory for Breast Health with the ForeCYTE Breast Health Test.

The ForeCYTE test, intended for the 110 million women in the U.S. ages 18-73, is a painless, quick and non-invasive procedure that can be performed in a physician's office. ForeCYTE can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight-year period before cancer can be detected by mammography or other means. Millennium HealthCare, through its wholly-owned operating subsidiaries, provides primary care physicians practices, physician groups and healthcare facilities of all sizes with cutting edge medical devices focused primarily on preventive care through early detection.

Dr. Steven Quay , Chairman, CEO & President  of Atossa Genetics, said, "We are extremely pleased that Millennium HealthCare will be distributing the ForeCYTE Breast Health devices to its healthcare practitioners. Millennium shares our passion about providing life-saving diagnostics to its healthcare professionals and we look forward to working closely with the Millennium team."

Chris Amandola , President of Millennium HealthCare, stated, "According to a recent American Cancer Society report, there were over 200,000 new cases of invasive breast cancer among women in 2012. Excluding cancers of the skin, breast cancer is the most common cancer among women, accounting for nearly 1 in 3 cancers diagnosed in U.S.

With over 38 million mammography procedures performed over the past year, our distribution channels are very excited by the prospect that Atossa's non-invasive test can offer physicians a simple and cost-effective preventive care solution to their patients for the early detection of precursors to breast cancer."

Dominick Sartorio , CEO of Millennium HealthCare, added, "Our team continues to explore the marketplace for new medical devices that can have a meaningful impact on improving patient care. Atossa Genetics' management team has done an outstanding job of advancing breast health care through their innovative medical devices and we look forward to a long relationship together."

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

In addition to the ForeCYTE Breast Health Test, Atossa markets the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

For additional information, please visit www.atossagenetics.com.

Atossa Genetics Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed April 5, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

About Millennium HealthCare, Inc.

Millennium HealthCare Inc. through its wholly owned operating subsidiaries provide primary care physician practices, physician groups and healthcare facilities of all sizes with cutting edge medical devices focused primarily on preventive care through early detection. The Company also provides advanced billing & coding services and practice development & management services specializing in cardiology:

Millennium Medical Devices targets partnerships with medical device companies that provide innovative medical devices that are cost effective, utilize cutting edge technology and are FDA approved. The devices the company distributes have been selected due to their ability to detect medical issues early with a positive medical outcome. All of the products the company distributes are reimbursable.

Millennium Coding & Billing offers all aspects of medical billing along with medical diagnosis and procedure coding and training for ICD-10. Our Clinical Documentation Improvement Program Services include concurrent and retrospective CDI Reviews, DRG Validation Services and secure remote and on-site coding.

Millennium Vascular Management Group offers physician practice development and management services to AMB-SURG facilities & physician practices with a focus on vascular disorders.

Millennium HealthCare Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995  

Certain written and oral statements made by us may constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Forward-looking statements are identified by such words and phrases as "we expect," "expected to," "estimates," "estimated," "current outlook," "we look forward to," "would equate to," "projects," "projections," "projected to be," "anticipates," "anticipated," "we believe," "could be," and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. Because they are forward-looking, they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.


'/>"/>
SOURCE Millennium HealthCare Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Millennium Research Group Sponsors Case Competition at Western University for Second Year
2. Millennium Research Group Identifies the Top Ten Trends in Medical Device Markets for 2013
3. Millennium Laboratories Angela Huskey Named Industry Pain Educator of the Year by American Society of Pain Educators
4. Millennium Surgical Corp. Named to Inc. 5000 List of Fastest Growing Private Companies for The Second Year
5. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
6. Pharmacy Industry Veteran Joins Millennium Pharmacy Systems as SVP Operations
7. SpineMark Corporation Partners with PhDx and Millennium Environmental to Create an ISO type Spine Protocol Management System
8. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
9. Court Preliminarily Deems Millennium Laboratories Press Release Misleading
10. Millennium Surgical Corp. Develops Online Sterilization Resource Center
11. Millennium Surgical Corp. Announces Sales Figures, Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ), ... lives of pets, today announced the submission to FDA ... Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive ... Zimeta for the control of pyrexia (fever) in horses ... --> --> The Chemistry, Manufacturing, and ...
(Date:2/11/2016)... , Feb. 11, 2016   Health 2.0 ... of new health technologies, announced today " 10 Year ... in health tech over the past ten years.   ... nearly a decade, Health 2.0 has served as the ... and connected with thousands of technologies, companies, innovators, and ...
(Date:2/11/2016)... 11, 2016  MiMedx Group, Inc. (NASDAQ: MDXG ... membrane and other birth tissues, human skin and bone, ... market advanced products and therapies, announced today that it ... Healthcare Conference in New York , ... Michael J. Senken , Chief Financial Officer and ...
Breaking Medicine Technology:
(Date:2/13/2016)... Angeles, California (PRWEB) , ... February 13, 2016 , ... ... help landing a date for the big day. A great outfit, flawless hair, and ... ashtray, they might as well resign themselves to a night at home with Rover. ...
(Date:2/13/2016)... Viejo, CA (PRWEB) , ... February 13, 2016 , ... ... ember particle overlays to footage all within Final Cut Pro X. Each user can ... control over 3D rotation, angle of view, blur, focus offset, hue, saturation, value, contrast, ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical ... in-kind gift of a VeinViewer® Vision vein finder for the nursing ... start an IV and draw blood, combining technology with traditional technique. , “VeinViewer ...
(Date:2/13/2016)... ... , ... DDi , a Makro company, makes it ... expertise in eClinical Solutions. DDi has built its solution competency with a unique ... clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & ... purpose of these scholarships is to encourage applicants to pursue a degree in their ... these two parishes. , “We have available jobs in St. Landry and Evangeline ...
Breaking Medicine News(10 mins):